Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Industry P/E
--
Debt to Equity
--
ROE
-4.31 %
ROCE
-365.69 %
Div. Yield
0 %
Book Value
1.36
EPS
-15.04
CFO
$-135.77 Mln
EBITDA
$-213.41 Mln
Net Profit
$-123.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| -99.00 | -80.19 | -96.08 | -99.67 | -89.90 | -- | -- |
|
BSE Sensex
| 5.34 | 9.68 | 8.04 | 13.44 | 15.08 | 21.17 | 11.60 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Vincerx Pharma (VINC)
| -77.45 | 15.69 | -89.99 | -51.27 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 53.38 | 9,739.38 | -- | -36.37 | |
| 37.08 | 9,967.87 | 20.55 | 23.13 | |
| 25.55 | 9,378.49 | -- | -30.53 | |
| 119.99 | 11,451.33 | 39.09 | 11.64 |
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform... combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California. Read more
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Co-Founder, Chairman & CEO
Dr. Ahmed M. Hamdy M.D.
Headquarters
San Mateo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vincerx Pharma Inc (VINC) stood at $ 8 Mln as on 31-Dec-24
The share price of Vincerx Pharma Inc (VINC) is $0.05 (NASDAQ) as of 12-May-2025 11:09 EDT. Vincerx Pharma Inc (VINC) has given a return of -89.9% in the last 3 years.
Vincerx Pharma Inc (VINC) has a market capitalisation of $ 0 Mln as on 09-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Vincerx Pharma Inc (VINC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vincerx Pharma Inc (VINC) and enter the required number of quantities and click on buy to purchase the shares of Vincerx Pharma Inc (VINC).
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
The CEO & director of Dr. Ahmed M. Hamdy M.D.. is Vincerx Pharma Inc (VINC), and CFO & Sr. VP is Dr. Ahmed M. Hamdy M.D..
There is no promoter pledging in Vincerx Pharma Inc (VINC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,098
|
|
|
1,086
|
|
|
1,077
|
|
|
1,006
|
| Vincerx Pharma Inc. (VINC) | Ratios |
|---|---|
|
Return on equity(%)
|
-431.29
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vincerx Pharma Inc (VINC) was $0 Mln.
$0.00
(
